Treatment of radiation-induced myelopathy with bevacizumab

Cañedo, Gustavo; Solis, I; Segundo, Carmen González‐San; Madero, Luís; Lassaletta, Álvaro

doi:10.1007/s12094-019-02209-5

Cited by 6 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like most reported cases, our patient experienced an improvement in both clinical and radiographic outcomes 18–20. In contrast, Psimaras et al reported four patients with RM and their outcomes after bevacizumab treatment 21.…”

Section: Discussionsupporting

confidence: 59%

Successful treatment of quadriparesis from radiation myelopathy with bevacizumab in a patient with metastatic breast cancer

Shah

Ranjan

2022

BMJ Case Rep

View full text Add to dashboard Cite

Radiation myelopathy (RM) is rare condition defined as injury to the spinal cord by ionising radiation. Due to improved survival in patients with advanced malignancies, there is a renewed interest in recognition and treatment of RM. There are very few reports on treatment of RM. A 64-year-old woman with metastatic oestrogen receptor, progesterone receptor weakly positive and human epidermal growth factor 2 negative breast, stereotactic radiosurgeries to brain metastases and a history of reradiation to the cervical spinal cord presented with neck pain, arm weakness, hyperreflexia and gait ataxia. RM was suspected and the patient was started on high dose corticosteroid therapy. However, the patient’s condition deteriorated and she developed quadriparesis. A timely treatment with an antivascular endothelial growth factor antibody, bevacizumab reversed her neurological deficits and preserved her walking ability. Our case illustrates a prompt diagnosis and successful treatment of RM with bevacizumab.

show abstract

Section: Discussionsupporting

confidence: 59%